ABCL - Why AbCellera Biologics Stock Sank 21.6% in October
Shares of AbCellera Biologics (NASDAQ: ABCL) fell 21.6% in October, according to data from S&P Global Market Intelligence . The biotech declined in response to news that an experimental pill developed by Merck has been shown to cut the risk of COVID-19-related hospitalization and death by half.
ABCL data by YCharts.
For further details see:
Why AbCellera Biologics Stock Sank 21.6% in October